▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #142 by analyst upside · 2026-09-27
TCRX
TScan Therapeutics, Inc.
Healthcare · Market Cap $23M · P/E 0x
ANALYST PRICE TARGET
+684.3%
implied upside to consensus target
Current Price $0.34
Consensus Target $2.67
Bull Target $6.0
Bear Target $1.0
Analysts Covering 3
ANALYST CONSENSUS - UNDERPERFORM
Strong Buy
0
Buy
0
Hold
2
Sell
1
52-Week Low $0.29
52-Week High $2.57
YTD Return -66.7%
FUNDAMENTALS
Market Cap $23M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.90
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $7M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.29
52-Week High $2.57
Current Price $0.34
Bear Target $1.0
Bull Target $6.0
● Now $0.34 ● Target $2.67
TRADING DATA
Avg Volume 867K
YTD Return -66.7%
Analyst Count 3
Consensus Underperform
Upside to Target +684.3%
Last Updated 2026-09-27

ANALYST SUMMARY

TScan Therapeutics, Inc. (TCRX) is currently trading at $0.34 with a Wall Street consensus price target of $2.67, implying potential upside of 684.3% over the next 12 months. 3 analysts currently cover TCRX, with a consensus rating of Underperform - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $6.0, while the most cautious has a target of $1.0.

TCRX operates in the Healthcare sector with a market capitalisation of $23M. The stock is down 66.7% year-to-date and is currently trading near the lower end of its 52-week range of $0.29 – $2.57.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

NCEL +680.6%
NewcelX Ltd.
$17M · P/E 5.3x · Strong Buy
VXRT +640.7%
Vaxart, Inc.
$109M · P/E 2.6x · Buy
DWTX +929.4%
Dogwood Therapeutics, Inc.
$46M · P/E 0.7x · Strong Buy
ETST +974.6%
Earth Science Tech, Inc.
$27M · P/E 9.3x · Hold
GTBP +988.5%
GT Biopharma, Inc.
$12M · P/E 0.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for TCRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-09-08 31% win rate (48 calls)
Wedbush ↓ Downgrade
Outperform → Neutral 2026-09-03 Building track record
Needham ↓ Downgrade
Buy → Hold 2026-09-02 20% win rate (5 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-08-12 31% win rate (48 calls)
Wedbush reit
Outperform → Outperform 2026-06-23 Building track record
Needham reit
Buy → Buy 2026-06-23 20% win rate (5 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-03-05 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-11-13 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
13
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →